Related Experiment Video
Updated: Aug 15, 2026
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Therapy insight: heart disease and the insulin-resistant patient
Stuart A Cook1, Tim Aitman, Rossi P Naoumova
1Clinical Cardiology at the Imperial College Faculty of Medicine, London, UK. stuart.cook@imperial.ac.uk
Insights
Insulin resistance is a global health crisis, impacting millions with type 2 diabetes and metabolic syndrome. Optimal management of heart disease in these patients requires multifactorial approaches, including advanced revascularization strategies.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Diseases
Background:
- Insulin resistance syndromes, including type 2 diabetes mellitus and metabolic syndrome, affect millions globally.
- Heart disease management in diabetic patients necessitates multifactorial risk-factor control beyond cholesterol.
- Coronary artery disease treatment in type 2 diabetes has evolved, with percutaneous coronary intervention gaining prominence.
Purpose of the Study:
- To review current strategies for managing coronary risk in insulin-resistant patients.
- To discuss advancements in revascularization techniques for type 2 diabetes patients with coronary arterial disease.
- To highlight the challenges in treating diabetic cardiomyopathy and heart failure.
Main Methods:
- Literature review of current treatment paradigms for insulin resistance, type 2 diabetes, and coronary artery disease.
- Analysis of the impact of drug-eluting stents and novel antiplatelet agents on percutaneous coronary intervention outcomes.
- Examination of risk-factor management and revascularization strategies in high-risk populations.
Main Results:
- Drug-eluting stents and new antiplatelet agents have significantly improved percutaneous coronary intervention for diabetic patients.
- Despite advances, consensus on optimal revascularization and risk-factor management for insulin-resistant patients with coronary disease is lacking.
- Effective therapies for diabetic cardiomyopathy and heart failure remain an unmet need.
Conclusions:
- Optimizing the prevention and treatment of metabolic syndrome and heart disease in insulin-resistant individuals is a critical global challenge.
- Further research is needed to establish clear guidelines for revascularization and risk-factor management in this population.
- Developing specific therapies for diabetic cardiomyopathy and heart failure is essential.
Abstract:
Insulin-resistance syndromes are of pandemic proportions; 150 million people worldwide and an estimated 43 million people in the US are currently affected by type 2 diabetes mellitus or metabolic syndrome respectively. Treatment of heart disease in the context of type 2 diabetes requires multifactorial risk-factor management, including lifestyle modification and drug treatment for comorbidities. Management of coronary risk extends beyond simple cholesterol lowering. Early use of cardiac imaging and, where appropriate, revascularization should be considered in high-risk or symptomatic patients. Traditionally, patients with type 2 diabetes and coronary arterial disease have been treated surgically, but percutaneous revascularization of these patients is increasingly common. Indeed, revascularization by use of drug-eluting coronary stents combined with administration of novel antiplatelet agents has revolutionized percutaneous coronary intervention in patients with type 2 diabetes. Despite these advances, there is no consensus of opinion regarding revascularization strategies or risk-factor management in insulin-resistant patients with symptomatic or prognostically important coronary arterial disease. Furthermore, specific therapies and preventative strategies for diabetic cardiomyopathy and heart failure in patients with type 2 diabetes remain elusive. The identification of optimized approaches for the prevention and treatment of the metabolic syndrome and heart disease in insulin-resistant, nondiabetic patients remains a major global challenge.
More Related Videos
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
01:26Type I Diabetes II: Pathophysiology
01:26Type II Diabetes I: Introduction
01:36Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...